Session Details

Morning Session 4 - Meet the Experts: Virus-Specific T Cells
Sunday, September 15, 2019 07:00 AM - 08:30 AM
Ballroom A
Join us for our last Morning Mental Workout to get your juices flowing for the rest of the day. Lynn O’Donnell, PhD – Director of the Cell Therapy Laboratory at The Ohio State University James Cancer Hospital and Solove Research Institute, Columbus, OH – will facilitate a lively discussion of topics related to technical, operational and regulatory challenges and controversies, professional development and perhaps topics like workplace politics and work-life balance with three internationally recognized experts in pre-clinical, translational development and clinical research of engineered virus-specific T cells (VSTs). Audience members will also have the opportunity to submit questions before and during the session using the Slido app, microphone and/or a loud voice. The goal is to be able to interact with and learn from these experts in a casual setting. Because of the rapidly growing interest in the topic of VSTs and vast experience of these experts, each will present a brief 10 minute overview of their work and career path before beginning separate, break-out Q&A discussions. We have added an additional 30 minutes to this Workout to allow for the full benefit and adequate time for attendees to hear from each of the three experts.

Chair:

Lynn O'Donnell, PhD, Ohio State University, James Cancer Hospital Columbus, USA

Speakers:

Virus specific T cell therapies- broadening applicability beyond CMV and EBV
Catherine Bollard, MBChB, MD, Children’s National Medical Center, USA
Learning objectives:
•      Understanding the breadth of T cell therapies targeting viruses
•      Understanding strategies for generating a VST “bank” for third party use
•      Discuss the use of naïve donor sources for VST products

Polyomaviruses
John Barrett, MDGeorge Washington University Hospital, USA
Learning objectives:
•      The diversity of human polyomaviruses and the diseases they cause
•      The normal immune response to the viruses and the effect of immune deficiency on viral reactivation
•      Cell therapies to treat BK Virus, JC virus and Merkel Cell Virus.

Third Party Virus Specific T cells (VSTs): Cincinnati Experience
Michael Grimley, MD, Cincinnati Children's Hospital Medical Center, USA
Learning objectives:
•      Discuss the manufacturing process for Viral Specific T cells (VSTs)
•      Clinical results from the use of third party VSTs
•      Indications for the use of third party VSTs